Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
BYL719 - Alpha-specific PI3K inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT04589650 EPIK-P2 (CBYL719F12201)
PIK3CA-related overgrowth spectrum
Phase 2
150
Proportion of participants with a response at Week 24
Arm 1: alpelisib vs. Arm 2: placebo during the 16 first weeks. for each cohort (adult,
pediatric)
Pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS)
Primary Analysis: H1-2023
NA
100 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation